Abstract
The Special Tuberculosis Treatment Information System (SITE-TB) arose mainly from the need to routinely monitor all persons with drug-resistant tuberculosis (DR-TB) in Brazil, as well as to qualify tuberculosis’ drug control. Developed by the Professor Hélio Fraga Reference Center and the Management Sciences for Health/Brazil Project, this online system was implemented in 2013 in all Brazilian states. In addition to DR-TB, the system registers people with drug-sensitive tuberculosis with special regimen indications, and those with nontuberculous mycobacterial infections identified by differential diagnosis of tuberculosis. All confirmed tuberculosis cases should be notified on the Notifiable Diseases Information System (SINAN). In situations where treatment with special regimens is necessary, the case is closed on SINAN and notified on SITE-TB. Professionals from tuberculosis reference centers report and monitor these cases on the system, as well as manage tuberculosis’ drugs.
Keywords:
Information Systems; Tuberculosis, Multidrug-Resistant; Surveillance; Epidemiology
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Legend:TB: tuberculosis.MDR-TB: multidrug-resistant tuberculosis.MR-TB: multiresistant tuberculosis.RR-TB: rifampicin resistant tuberculosis tested with RMT-TB.RMT-TB: rapid molecular test for tuberculosis.TBWeb: Tuberculosis Case Notification and Monitoring System.SITE-TB: Special Tuberculosis Treatment Information System.R: rifampicin.H: isoniazid.Z: pyrazinamide.E: ethambutol.PNCT: National Tuberculosis Control Program.Anti-TB: anti-tuberculosis.
Legend:TB: tuberculosis.MDR-TB: multidrug-resistant tuberculosis.SITE-TB: Special Tuberculosis Treatment Information System.
Legend:TB: tuberculosisDR-TB: drug-resistant tuberculosisSINAN: Notifiable Diseases Information SystemSITE-TB: Special Tuberculosis Treatment Information SystemNTM: nontuberculous mycobacterial infectionsAnti-TB: anti-tuberculosisa) Cases with mono-resistance to isoniazid or rifampicin should be closed on SINAN as DR-TB and then notified on SITE-TB, regardless of the treatment regimen used. The following will not be considered to be special treatment (i) TB-HIV coinfection cases in which rifampicin is replaced by rifabutin and (ii) cases with some kind of complication during treatment with basic regimen which led to the drug-by-drug regimen. The latter cases should only be notified on SITE-TB after definition of the definitive special regimen.
Legend:SUS card: Brazilian National Health System service user cardSINAN: Notifiable Diseases Information SystemDOT: directly observed treatmentRMT-TB: rapid molecular test for tuberculosisST: sensitivity testDR-TB: drug-resistant tuberculosisHIV: human immunodeficiency virusAIDS: acquired immunodeficiency syndrome